An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies. Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Drake, M J, Robson, W, Mehta, P, Schofield, I, Neal, D E, Leung, H Y
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2003
Fag:
Clinical
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2377091/
https://ncbi.nlm.nih.gov/pubmed/12644816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600817
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker